Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4e)-4-Aminohex-4-Enoic Acid is a synthetic gamma amino acid derivative with the molecular formula C6H11NO2 and a molecular weight of approximately 129.16 g/mol[1][2][8]. It is classified as an experimental small molecule compound and has not been approved for clinical use in any country[1]. The compound acts as an inhibitor of the enzyme 4‑aminobutyrate aminotransferase, mitochondrial (also known as GABA transaminase or GABA-T), which plays a key role in the catabolism of gamma‑aminobutyric acid (GABA), an important inhibitory neurotransmitter in the central nervous system[3][7]. By inhibiting this enzyme, compounds like (4e)-4-Aminohex‑4‑Enoic Acid can potentially increase brain GABA levels. This mechanism is similar to that of certain antiepileptic drugs targeting GABA metabolism, though there are no indications that this specific compound has advanced beyond experimental status or entered clinical trials for epilepsy or other neurological disorders[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (4e)-4-aminohex-4-enoic acid.